ClinicalTrials.gg
CompletedNCT01613690Updated Dec 19, 2020

Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

A Phase 1 interventional study of NVA237 in Renal Impairment, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies in Renal Insufficiency by Novartis — 1 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Novartis.

Enrollment
13th of 36
48 · median 37
Started
2010
with 1 other
Phase 1
21 of 37
1 open now
Registered
17th of 37
by date

Among the 37 studies in Renal Insufficiency by Novartis, this one is the 13th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2010, is one of 21 in phase 1, and was the 17th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

1 of the 37 studies in Renal Insufficiency by Novartis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.

03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Renal impairment
  • NVA237
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects age 18 to 70 years of age inclusive.
  • Female subjects of must be using two acceptable methods of , (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the study, through study completion.
  • Subjects must weigh at least 50 kg to participate in the study, and must have a (BMI) within the range of 17 to 35 kg/m2.
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written
  • For renal insufficient subjects only - Subjects must have stable renal disease without evidence of renal progressive disease (for the purpose of this study stable renal disease will be defined as no significant change for 12 weeks).
  • For health subjects only - A serum creatinine within the normal range and an >80 mL/min/1.73 m2.
  • For health subjects only - Matched to at least one renal impaired subjects undergoing study by age (±5 years), sex and weight (±10% BMI).

Exclusion criteria

Exclusion Criteria:

  • Smokers (use of tobacco products in the previous 3 months). Smokers will be defined as any subject who reports tobacco use and/or who has a urine cotinine ≥ 500 ng/mL. If non-smoking subject are too difficult to recruit, smokers may be allowed to participate in the study provided they commit to smoke no more than 10 cigarettes/day during the days of PK-assessment
  • For healthy subjects, use of any prescription drugs, herbal and fitness/bodybuilding/athletic performance-enhancing supplements, within four (4) weeks prior to initial dosing, and/or over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing
  • Recent (within the last three [3] years) and/or recurrent history of autonomic dysfunction (e.g., recurrent episodes of fainting (unless related to water withdrawal during dialysis), palpitations, etc).
  • Recent (within the last three [3] years) and/or recurrent history of acute or chronic bronchospastic disease (including asthma and , treated or not treated).
  • History of multiple and recurring allergies or allergy to the compound/compound class being used in this study.
  • Total WBC count which falls outside the range of 3000-12,000/μL, or \<100,000/μl at screening.
  • History of immunodeficiency diseases, including a positive (ELISA and Western blot) test result.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Healthy volunteers

    control group receiving 100 μg NVA237

    Drug: NVA237

  • Experimental
    Mild renal impairment

    (eGFR 50-80 mL/min/1.73m2) receiving 100 μg NVA237

    Drug: NVA237

  • Experimental
    Moderate renal impairment

    (eGFR 30-49 mL/min/1.73m2) receiving 100 μg NVA237

    Drug: NVA237

  • Experimental
    Severe renal impairment

    (eGFR \<30 mL/min1.73m2) receiving 100 μg NVA237

    Drug: NVA237

  • Experimental
    End-stage subjects requiring dialysis (ESRD)

    receiving 100 μg NVA237

    Drug: NVA237

Interventions

  • DrugNVA237

    NVA237 is administered via a BREEZHALER device

06

What researchers measure

Primary outcomes

  1. Concentration of NVA2105 using PK parameter of primary interest - area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  2. Concentration of NVA2105 using PK parameter of primary interest - maximum plasma concentration (Cmax)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  3. Concentration of NVA2105 using PK parameter of primary interest - renal clearance (CLR)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  4. Concentration of NVA2105 using PK parameter of secondary interest - time to Cmax (Tmax)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  5. Concentration of NVA2105 using PK parameter of secondary interest - AUC extrapolated to infinity (AUCinf)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  6. Concentration of NVA2105 using PK parameter of secondary interest - terminal elimination half-life, determined from plasma concentrations and urinary excretion rates (T1/2)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  7. Concentration of NVA2105 using PK parameter of secondary interest - apparent systemic clearance (CL/F)

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  8. Concentration of NVA2105 using PK parameter - amount excreted into the urine from time 0 to 96 h post-dose (Ae0-96h)

    Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  9. Concentration of NVA2105 using PK parameter - T1/2

    Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

  10. Concentration of NVA2105 using PK parameter - CLR

    Samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Urine, Analyte: NVA237

    Time frame: Day 1, 2, 3, 4 and 5

Secondary outcomes

  1. Change in effect of dialysis in End-stage subjects requiring dialysis (ESRD) using PK parameter Cmax

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1 of each treatment period

  2. Change in effect of dialysis in End-stage subjects requiring dialysis using PK parameter AUClast

    Blood samples will be collected at various time points on each visit day; Compound: NVA237 100ug, Matrix: Plasma, Analyte: NVA237

    Time frame: Day 1 of each treatment period

  3. Safety and tolerability of a single inhalation dose of 100μg NVA237 in subjects with mild, moderate, severe, and end-stage renal impairment

    Adverse events will be based on evaluation of physical signs, electrocardiograms and clinical laboratory assessments

    Time frame: Reviewed during each study visit

07

Study locations

1 site
  • Novartis Investigative Site
    Moscow, Russian Federation
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2012
First posted
Jun 7, 2012
Start
Jun 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01613690
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
Jun 2010
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Dec 19, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion